Entrada Therapeutics
Entrada Therapeutics develops intracellular therapeutics targeting neuromuscular, immunological, ocular, and metabolic diseases using its proprietary EEV™ Platform.
Company Overview
Entrada Therapeutics specializes in developing intracellular therapeutics to treat severe diseases. The company utilizes its proprietary EEV™ Platform to target previously inaccessible, undruggable disease-causing targets within cells. This unique technology is at the heart of their mission to create effective therapeutic solutions.
Therapeutic Focus Areas
Entrada Therapeutics concentrates on therapeutic areas such as neuromuscular, immunological, ocular, and metabolic diseases. Their current pipeline features a diverse and expanding portfolio of oligonucleotide, antibody, and enzyme-based programs. Notably, the company is advancing treatments for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1.
EEV™ Platform
Entrada Therapeutics employs its proprietary EEV™ Platform to develop intracellular therapeutics. This technology is designed to engage disease-causing targets within cells that have previously been considered inaccessible and undruggable, opening new avenues for therapeutic intervention.
Commitment to Research and Transparency
Entrada Therapeutics is committed to publishing their research results in a transparent, scientifically accurate, and timely manner. Their dedication to transparency ensures that their findings are accessible and reliable for the scientific community and the public.
DREAMS Grant Program
Through their competitive grant program, DREAMS, Entrada Therapeutics strives to advance diversity, equity, inclusion, and accessibility within the Duchenne muscular dystrophy community. This initiative underscores their commitment to fostering an inclusive environment and supporting underrepresented groups.
Accessibility Partnership
Entrada Therapeutics partners with Perkins Access to ensure their website conforms to the W3C WCAG Version 2.1 Level AA standards for accessibility. This partnership reflects their dedication to making their digital content accessible to a wider audience, including individuals with disabilities.
